文献速递技术与安全CT

门诊患者CT检查中使用非离子型对比剂的安全性:473,482例患者的回顾性多中心分析

Safety of non-ionic contrast media in CT examinations for out-patients: retrospective multicenter analysis of 473,482 patients.
PubMed 文献 · Eur Radiol · 2024-03-08

该回顾性多中心研究纳入2017年1月1日至2021年12月31日期间在三家机构接受静脉注射非离子型碘对比剂(NICM)的门诊患者473,482例,总体药物不良反应(ADR)发生率为0.110%(522/473,482),急性ADR发生率为0.099%(469/473,482),严重ADR发生率为0.0004%(2/473,482)。碘普罗胺与急性ADR风险升高相关,碘克沙醇320更常观察到迟发ADR;夏季(调整OR=1.579;p=0.035)和秋季(调整OR=1.925;p<0.001)是急性ADR的危险因素。

要点

  • 门诊患者使用NICM总体安全,ADR发生率0.110%,急性ADR 0.099%,严重ADR 0.0004%。
  • 碘普罗胺与急性ADR风险升高相关,碘克沙醇320更常观察到迟发ADR。
  • 夏季和秋季是急性ADR的危险因素(调整OR分别为1.579和1.925)。

核心结论

  • 门诊患者使用NICM总体安全,ADR发生率低;对比剂类型(碘普罗胺)和季节(夏季和秋季)与急性ADR风险升高相关,碘克沙醇更常观察到迟发ADR。

研究设计与样本

  • 回顾性多中心分析,纳入2017年1月1日至2021年12月31日期间三家机构接受静脉注射NICM的门诊患者473,482例(平均年龄55.22±14.85岁;男性253,499例),记录ADR发生情况和临床信息,采用卡方检验、泊松回归和逻辑回归分析ADR潜在危险因素及其与人口学、季节和NICM类型的关系。

诊断标准与关键数值

  • 总体ADR发生率为0.110%(522/473,482),急性相关药物反应发生率为0.099%(469/473,482),严重ADR发生率为0.0004%(2/473,482)。
  • 碘普罗胺与急性ADR风险升高相关。
  • 碘克沙醇320更常观察到迟发ADR。
  • 对急性ADR患者与对照组(按年龄、性别、NICM、开方科室和机构1:1匹配)进行多因素逻辑回归显示,夏季为急性ADR的危险因素(调整OR=1.579;p=0.035),秋季为急性ADR的危险因素(调整OR=1.925;p<0.001)。
  • 基础疾病和扫描身体部位与ADR发生率升高无关。

临床应用与阅片要点

  • 原文指出,与住院患者相比,门诊患者可能因缺乏广泛的风险筛查、护理较少和通量压力较高而暴露于更高风险。
  • 原文认为,来自大规模人群的NICM安全性数据可补充指南并避免歧义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study aimed to explore the incidence of and potential risk factors for adverse drug reactions (ADRs) after non-ionic iodinated contrast media (NICM) administration for CT exams in out-patient settings in China.

MATERIALS AND METHODS: A total of 473,482 out-patients who underwent intravenous NICM between January 1st, 2017, and Dec 31st, 2021, were retrospectively enrolled from three institutions. The occurrence of ADRs and clinical information were recorded. Chi-square test, Poisson regression, and logistic regression analyses were used to evaluate potential ADR risk factors and correlation with demographics, season, and NICM type.

RESULTS: Among the 473,482 patients (mean age 55.22 ± 14.85; 253,499 male) who received intravenous NICM, the overall ADR incidence was 0.110% (522 of 473,482), with 0.099% acute-related drug reactions (469 of 473,482) and 0.0004% serious ADRs (two of 473,482). Iopromide was associated with a higher risk of acute ADRs. Late ADRs were more frequently observed with iodixanol 320. Multi-level logistic regression of patients with acute ADRs and a control group (matched 1:1 for age, gender, NICM, prescriber department, and institution) showed that summer (adjusted OR = 1.579; p = 0.035) and autumn (adjusted OR = 1.925; p < 0.001) were risk factors of acute ADRs. However, underlying disease and scanned body area were not related to a higher ADR incidence.

CONCLUSION: The use of NICM for out-patients is in general safe with a low ADR incidence. The type of contrast medium (iopromide) and the seasons (summer and autumn) were associated with a higher risk of acute ADRs. Late ADRs were more often observed with iodixanol.

CLINICAL RELEVANCE STATEMENT: In comparison to in-patients, out-patients may be exposed to higher risk due to a lack of extensive risk screening, less nursing care, and higher throughput pressure. Safety data about NICM from a large population may complement guidelines and avoid ambiguity.

KEY POINTS: • The incidence and risk factors for adverse events after using non-ionic iodinated contrast media are complex in out-patients. • Non-ionic iodinated contrast media are safe for out-patients and the overall incidence of adverse drug reactions was 0.110%. • There is a higher risk of acute adverse drug reactions in summer and autumn.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Zeng W, Tang J, Xu X, et al. Safety of non-ionic contrast media in CT examinations for out-patients: retrospective multicenter analysis of 473,482 patients. Eur Radiol. 2024. PMID: 38457038. doi:10.1007/s00330-024-10654-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。